Anzeige
❌
Mehr »
Dienstag, 10.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 1,42 USD bis Juni 2027, die 200 % Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHDZ | ISIN: AU0000043945 | Ticker-Symbol: PBN
Stuttgart
10.11.26 | 12:32
0,153 Euro
-10,00 % -0,017
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,1540,18412:51

Aktuelle News zur ALTERITY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.10.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Releases Appendix 4C - Q1 FY27 Quarterly Cash Flow Report & Corporate Update2
30.10.Alterity Therapeutics Confirms Phase 3 Trial Pathway for ATH4342
30.10.ALTERITY THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report2
23.10.ALTERITY THERAPEUTICS LIMITED: Proposed issue of securities - ATH1
23.10.ALTERITY THERAPEUTICS LIMITED: Notification regarding unquoted securities - ATH1
ALTERITY THERAPEUTICS Aktie jetzt für 0€ handeln
23.10.ALTERITY THERAPEUTICS LIMITED: Notification regarding unquoted securities - ATH1
21.10.ALTERITY THERAPEUTICS LIMITED: Notice of Annual General Meeting/Proxy Form1
21.10.ALTERITY THERAPEUTICS LIMITED: Changes to Managing Director Terms of Employment2
19.10.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
18.10.ALTERITY THERAPEUTICS LIMITED: Alterity to Present at the Craig-Hallum Biotech Conference1
09.10.ALTERITY THERAPEUTICS LIMITED: Alterity to Present at Canaccord Drug and Device Conference-
05.10.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders459ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of...
► Artikel lesen
05.10.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
05.10.ALTERITY THERAPEUTICS LIMITED: Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA2
25.09.ALTERITY THERAPEUTICS LIMITED: Date of AGM and Closing Date for Director Nominations2
23.09.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
23.09.ALTERITY THERAPEUTICS LIMITED: Corporate Presentation September 20261
18.09.ALTERITY THERAPEUTICS LTD - S-8, Securities to be offered to employees in employee benefit plans1
18.09.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics to Present at ASX SMIDcaps Conference1
16.09.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer4
1 2 3 4 5 Weiter >>
101 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1